Indian government expresses doubts about price negotiations for patented pharmaceuticals
A report from the Committee on Price Negotiation for Patented Drugs suggests that there is further need for price controls and compulsory licenses.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: